SI-BONE, Inc. (NASDAQ:SIBN) Receives $24.50 Average Target Price from Analysts

Shares of SI-BONE, Inc. (NASDAQ:SIBN) have been given a consensus recommendation of “Buy” by the six research firms that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $24.50.

Several equities research analysts have issued reports on the company. Truist Financial reissued a “buy” rating and set a $22.00 target price (up previously from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Needham & Company LLC lifted their price target on SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 target price on shares of SI-BONE in a research report on Tuesday, February 25th.

SI-BONE Price Performance

NASDAQ:SIBN opened at $16.95 on Monday. SI-BONE has a one year low of $11.70 and a one year high of $19.16. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The stock has a market cap of $719.58 million, a PE ratio of -18.42 and a beta of 1.17. The stock has a 50 day moving average price of $16.27 and a 200 day moving average price of $14.85.

SI-BONE (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The firm had revenue of $49.00 million during the quarter, compared to analysts’ expectations of $48.87 million. Equities research analysts expect that SI-BONE will post -0.78 EPS for the current fiscal year.

Insider Activity at SI-BONE

In other SI-BONE news, CFO Anshul Maheshwari sold 5,304 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total transaction of $73,778.64. Following the transaction, the chief financial officer now owns 189,319 shares of the company’s stock, valued at $2,633,427.29. This represents a 2.73 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Anthony J. Recupero sold 3,670 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total value of $51,013.00. Following the transaction, the insider now directly owns 222,814 shares in the company, valued at approximately $3,097,114.60. This represents a 1.62 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,311 shares of company stock valued at $130,356. 3.90% of the stock is owned by corporate insiders.

Institutional Trading of SI-BONE

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Champlain Investment Partners LLC increased its holdings in shares of SI-BONE by 14.7% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock worth $39,145,000 after buying an additional 358,821 shares during the last quarter. American Century Companies Inc. raised its position in SI-BONE by 11.0% in the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company’s stock valued at $33,341,000 after purchasing an additional 236,167 shares during the period. Silvercrest Asset Management Group LLC lifted its stake in shares of SI-BONE by 21.9% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company’s stock worth $27,392,000 after purchasing an additional 350,970 shares in the last quarter. Bellevue Group AG boosted its position in shares of SI-BONE by 4.1% in the third quarter. Bellevue Group AG now owns 1,444,109 shares of the company’s stock worth $20,189,000 after buying an additional 56,500 shares during the period. Finally, Paradigm Capital Management Inc. NY grew its stake in shares of SI-BONE by 5.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company’s stock valued at $19,432,000 after buying an additional 69,831 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.